Aquestive Therapeutics, Inc. will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 14, 2026. The Aquestive management team is scheduled to host 1x1 investor meetings during the forum. The event will feature panels discussing key therapeutic themes in immunology and inflammation (I&I), and metabolism.

Aquestive operates as a pharmaceutical company advancing medicines through innovative science and delivery technologies. The company serves as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees. Its headquarters are in New Jersey, with U.S.-based manufacturing facilities in Indiana.

The company is the exclusive manufacturer of four commercialized products marketed by licensees across six continents. These products utilize proprietary technologies such as PharmFilm®. Aquestive's AdrenaVerse™ platform includes a library of more than 20 epinephrine prodrugs for potential allergy and dermatological indications.

Aquestive is advancing Anaphylm™ (dibutepinephrine) sublingual film for treating severe allergic reactions, including anaphylaxis. Additionally, the company is developing AQST-108 (epinephrine prodrug) topical gel for dermatological conditions such as alopecia areata.

Aquestive Therapeutics has filed a prospectus with the Securities and Exchange Commission (SEC) for an offering of 230,271 common shares on behalf of selling shareholders. The filing indicates that the offering is being made by the selling shareholders, and the company will not receive any proceeds from the sale of these shares. The prospectus details the terms of the offering but does not specify the price per share or the timing of the sale.

Offering Details

The offering consists of 230,271 common shares, which are being sold by existing shareholders rather than the company itself. This means that Aquestive Therapeutics will not generate any capital from this transaction. The shares will be sold through the methods described in the prospectus, which may include sales on the NASDAQ Global Market or in negotiated transactions.

Key Information

The prospectus is available on the SEC's website, providing full disclosure regarding the selling shareholders and the terms of the offering. Investors are advised to review the document for complete details.